



# CML: the promise of treatment-free remission



## The CML treatment process



According to the European LeukemiaNet (ELN) guidelines, TFR should be considered as the new treatment goal in CML<sup>1</sup>

30–50%

75–70%

40–50%

of patients receiving 1<sup>st</sup> generation TKIs achieve MR<sup>2–4</sup>

of patients on 2<sup>nd</sup> generation TKIs achieve MR<sup>5–6</sup>


in deep molecular response (DMR) can be relapse-free after stopping TKIs<sup>7–9</sup>

## Reasons for stopping TKIs<sup>9–11</sup>




A survey showed that 58% of patients did not want to stop TKIs due to fears of disease recurrence & mortality<sup>12</sup>

## Factors affecting TFR success<sup>9,13–16</sup>



## Trial data



## TKI withdrawal

Symptoms include diffuse myalgia, arthralgia and other musculoskeletal pains affecting arms, hips and extremities<sup>54</sup>



Mechanisms of withdrawal symptoms are unclear but can be controlled by tapering TKI dose in the months leading to discontinuation<sup>55</sup>



1. Hochhaus A, et al. Leukemia 2020;34:966–84; 2. Branford S, et al. Blood 2013;121:3818–24; 3. Hochhaus A, et al. Leukemia 2016;30:1044–54; 4. Cortes JE, et al. J Clin Oncol 2016;34:2333–40; 5. Maiti A, et al. Cancer 2020;126:1502–11; 6. Masarova L, et al. Cancer 2020;126:1448–59; 7. Etienne GJ, et al. Clin Oncol 2017;35:298–305; 8. Ross DM, et al. Blood 2013;122:515–22; 9. Saussele S, et al. Lancet Oncol 2018;19:747–57; 10. Wang Z, et al. Exp Rev Clin Pharmacol 2021;14:445–56; 11. Abruzzese E, et al. Mediter J Haematol Infect Dis 2014;6:e2014028; 12. Goldberg S, et al. Blood 2020;61:650–9; 13. Shah NP, et al. Leuk Lymphoma 2020;61:650–9; 14. Rea D, et al. Blood 2017;129:846–54; 15. Etienne G, et al. Cancers 2020;12:2521; 16. Lee SE, et al. Haematologica 2016;101:717–23; 17. Mahon FX, et al. Lancet Oncol 2010;11:1029–35; 18. Etienne G, et al. J Clin Oncol 2017;35:298–305; 19. Ross DM, et al. Blood 2013;122:515–22; 20. Rousselot P, et al. Blood 2013;122:381; 21. Lee SE, et al. Haematologica 2016;101:717–23; 22. Kim DDH, et al. Blood 2016;128:1922; 23. Diral E, et al. Blood 2020;136:2237–40; 24. Takahashi N, et al. Int J Hematol 2018;107:185–93; 25. Fujisawa S, et al. J Clin Oncol 2019;37:7005; 31. Mahon FX, et al. Blood 2020;136(suppl1):29–30; 32. Imagawa J, et al. Lancet Hematol 2015;2:e528–35; 33. Okada M, et al. Clin Lymphoma Myeloma Leuk 2018;18:353–60.e1; 34. Kumagai T, et al. Cancer Sci 2020;111:2923–34; 35. Shah NP, et al. Leuk Lymphoma 2020;61:650–9; 37. Kimura S, et al. Lancet Haematol 2020;7:e218–25; 38. Rea D, et al. Blood 2017;129:846–54; 40. Etienne G, et al. Cancers 2020;12:2521; 41. Kim DDH, et al. Blood 2016;128:1922; 42. Legros L, et al. Cancer 2017;123:4403–10; 43. Legros L, et al. Blood 2019;134(suppl 1):28; 44. Lee SE, et al. Blood 2020;136(suppl 1):51–50; 45. Hernández-Boluda JC, et al. Blood Cancer Journal 2018;8:91; 46. Fava C, et al. Haematologica 2019;104:1589–96; 47. Kwok M, et al. EHA Learning Center. 2019, PB1946; 48. Dengler J, et al. HemaspHERE 2019;3(S1):PF418; 49. Cerveira N, et al. EHA Learning Center 2018; Abstract 216327:PB1963; 50. Alarcón-Payer C, et al. HemaSphere 2019;3(S1):884; 51. Flygt H, et al. Br J Haematol 2021;193:915–21; 52. Chamoun K, et al. J Hematol Oncol 2019;12:1; 53. Ureshino H, et al. Hematol Oncol 2021;39:549–57; 54. Katagiri S, et al. Leuk Res Rep 2017;7:33–5; 55. Clark RE, et al. Curr Hematol Malig Rep 2019;14:507–14.